KYNB

#4538
Kyntra Bio, Inc. Common Stock
7.37 USD
+4.10%
Sector:
Base: USD
Profit Currency: USD
Daily Range
7.37
7.37
Year Range
6.32
9.70
Daily Change
+4.10%
Monthly Change
+3.08%
6 month change
-22.50%
Year Change
-22.50%
Previous Close
7.08
Open
7.37
Bid
Ask
Low
7.37
High
7.37
Volume
2
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 29.83 M
  • Employee 34
  • Founded 1993
  • CEO N/A
  • Website www.kyntrabio.com
  • Headquarter California, United States
  • FIGI BBG000FW5ZL6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.